Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Receivables (2024 - 2025)

Stoke Therapeutics has reported Receivables over the past 2 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Receivables at $7.9 million for Q4 2025, up 233.83% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (up 233.83% YoY), and the annual figure for FY2025 was $7.9 million, up 233.83%.
  • Receivables for Q4 2025 was $7.9 million at Stoke Therapeutics, down from $10.8 million in the prior quarter.
  • Over the last five years, Receivables for STOK hit a ceiling of $10.8 million in Q3 2025 and a floor of $2.4 million in Q4 2024.